Skip to main content

Visual Aura

  • 330 Accesses

Abstract

Visual aura is a combination of transient positive and negative visual phenomena that can be seen in migraine, epilepsy, and stroke. While the pathophysiology of the visual aura in migraine is widely accepted to be due to cortical spreading depression (CSD), the trigger for CSD in humans is not clear. Multiple studies have demonstrated an increased risk of stroke in patients who have migraine with aura, especially women under age 45, and an increased incidence of patent foramen ovale (PFO). Despite distinct differences in pathophysiology, migraine with and without aura are largely treated the same. There is one FDA-approved treatment specifically for the acute phase of migraine with aura: single-pulse transcranial magnetic stimulation (sTMS). Other studies looking at the treatment of migraine with aura are aimed at N-methyl-D-aspartate (NMDA) receptor antagonist medications to reduce glutamate release due to the proposed role of NMDA receptors in CSD.

Keywords

  • Visual aura
  • Migraine with aura
  • Cortical spreading depression (CSD)
  • Patent foramen ovale (PFO)
  • Combined hormonal contraceptive (CHC)
  • Single-pulse transcranial magnetic stimulation (sTMS)
  • Ketamine
  • Memantine
  • Topiramate
  • Lamotrigine
  • Magnesium
  • Triptans

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-74103-7_19
  • Chapter length: 10 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   129.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-74103-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   119.99
Price excludes VAT (USA)
Hardcover Book
USD   169.99
Price excludes VAT (USA)

References

  1. Viana M, Tronvik EA, Do TP, Zecca C, Hougaard A. Clinical features of visual migraine aura: a systematic review. J Headache Pain. 2019;20(1):64.

    CrossRef  Google Scholar 

  2. Schankin CJ, Viana M, Goadsby PJ. Persistent and repetitive visual disturbances in migraine: a review. Headache J Head Face Pain. 2017;57(1):1–16.

    CrossRef  Google Scholar 

  3. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2013;33(9):629–808.

    Google Scholar 

  4. Russell M, Rasmussen B, Fenger K, Olesen J. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia. 1996;16(4):239–45.

    CAS  CrossRef  Google Scholar 

  5. Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol. 1944;7(6):359–90.

    CrossRef  Google Scholar 

  6. Hadjikhani N, Sanchez del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98(8):4687–92.

    CAS  CrossRef  Google Scholar 

  7. Cutrer FM, Sorensen AG, Weisskoff RM, Østergaard L, Rio MSD, Lee EJ, et al. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol. 1998;43(1):25–31.

    CAS  CrossRef  Google Scholar 

  8. Charles AC, Baca SM. Cortical spreading depression and migraine. Nat Rev Neurol. 2013;9(11):637–44.

    CrossRef  Google Scholar 

  9. Hartl E, Angel J, Rémi J, Schankin CJ, Noachtar S. Visual auras in epilepsy and migraine – an analysis of clinical characteristics. Headache J Head Face Pain. 2017;57(6):908–16.

    CrossRef  Google Scholar 

  10. Shams PN, Plant GT. Migraine-like visual aura due to focal cerebral lesions: case series and review. Surv Ophthalmol. 2011;56(2):135–61.

    Google Scholar 

  11. Mattle HP, Evers S, Hildick-Smith D, Becker WJ, Baumgartner H, Chataway J, et al. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Eur Heart J. 2016;37(26):2029–36.

    CrossRef  Google Scholar 

  12. Post MC, van Gent MWF, Plokker HWM, Westermann CJJ, Kelder JC, Mager JJ, et al. Pulmonary arteriovenous malformations associated with migraine with aura. Eur Respir J. 2009;34(4):882–7.

    CAS  CrossRef  Google Scholar 

  13. Sheikh HU, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review. Headache J Head Face Pain. 2018;58(1):5–21.

    CrossRef  Google Scholar 

  14. Donaghy M, Chang C, Poulter N. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatry. 2002;73(6):747–50.

    CAS  CrossRef  Google Scholar 

  15. Bousser M-G, Conard J, Kittner S, de Lignières B, MacGregor EA, Massiou H, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. Cephalalgia. 2000;20(3):155–6.

    CAS  CrossRef  Google Scholar 

  16. Champaloux SW, Tepper NK, Monsour M, Curtis KM, Whiteman MK, Marchbanks PA, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;216(5):489.e1–489.e7.

    Google Scholar 

  17. Nightingale AL, Farmer Richard DT. Ischemic stroke in young women. Stroke. 2004;35(7):1574–8.

    CrossRef  Google Scholar 

  18. Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373–80.

    CrossRef  Google Scholar 

  19. Tietjen GE, Collins SA. Hypercoagulability and migraine. Headache. 2018;58(1):173–83. https://doi.org/10.1111/head.13044.

    CrossRef  PubMed  Google Scholar 

  20. Bu F, Du R, Li Y, Quinn JP, Wang M. NR2A contributes to genesis and propagation of cortical spreading depression in rats. Sci Rep [Internet]. 2016 [cited 2020 Jul 19];6.

    Google Scholar 

  21. Lauritsen C, Mazuera S, Lipton RB, Ashina S. Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. J Headache Pain [Internet]. 2016 [cited 2020 Jul 19];17(1).

    Google Scholar 

  22. Pomeroy JL, Marmura MJ, Nahas SJ, Viscusi ER. Ketamine infusions for treatment refractory headache. Headache J Head Face Pain. 2017;57(2):276–82.

    CrossRef  Google Scholar 

  23. Afridi SK, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013;80(7):642–7.

    CAS  CrossRef  Google Scholar 

  24. Aracava Y, Pereira EFR, Maelicke A, Albuquerque EX. Memantine blocks α7* nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther. 2005;312(3):1195–205.

    CAS  CrossRef  Google Scholar 

  25. Rammes G, Rupprecht R, Ferrari U, Zieglgänsberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkylcyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001;306(1):81–4.

    Google Scholar 

  26. Charles A, Flippen C, Romero Reyes M, Brennan KC. Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain. 2007;8(4):248–50.

    CAS  CrossRef  Google Scholar 

  27. Noruzzadeh R, Modabbernia A, Aghamollaii V, Ghaffarpour M, Harirchian MH, Salahi S, et al. Memantine for prophylactic treatment of migraine without aura: a randomized double-blind placebo-controlled study. Headache J Head Face Pain. 2016;56(1):95–103.

    Google Scholar 

  28. Jain AC, Sethi NC, Babbar PK. A clinical electroencephalographic and trace element study with special reference to zinc, copper and magnesium in serum and cerebrospinal fluid (CSF) in cases of migraine. J Neurol. 1985;232(Supplement 1):161.

    Google Scholar 

  29. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002;22(5):345–53.

    CAS  CrossRef  Google Scholar 

  30. Orr SL. Diet and nutraceutical interventions for headache management: a review of the evidence. Cephalalgia. 2016;36(12):1112–33.

    CrossRef  Google Scholar 

  31. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia. 1995;36(s2):S2–12.

    CAS  CrossRef  Google Scholar 

  32. Brandes JL. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291(8):965.

    CAS  CrossRef  Google Scholar 

  33. Silberstein SD. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61(4):490.

    CrossRef  Google Scholar 

  34. Silberstein SD, Hulihan J, Rezaul Karim M, Wu S-C, Jordan D, Karvois D, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006;28(7):1002–11.

    CAS  CrossRef  Google Scholar 

  35. D’Andrea G, Granella F, Cadaldini M, Manzoni G. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia. 1999;19(1):64–6.

    CrossRef  Google Scholar 

  36. Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura—a pilot study. Cephalalgia. 1999;19(1):58–63.

    CAS  CrossRef  Google Scholar 

  37. Lampl C, Katsarava Z, Diener H, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry. 2005;76(12):1730–2.

    CAS  CrossRef  Google Scholar 

  38. Pascual J, Caminero AB, Mateos V, Roig C, Leira R, García-Moncó C, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache J Head Face Pain. 2004;44(10):1024–8.

    CrossRef  Google Scholar 

  39. Steiner TJ, Findley LJ, Yuen AWC. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura: Cephalalgia [Internet]. 2016 [cited 2020 Sep 25].

    Google Scholar 

  40. Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache J Head Face Pain. 2007;47(3):402–12.

    Google Scholar 

  41. Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJ, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol. 2013;12(5):454–61.

    CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Woodward, K.M., Vuppala, AA.D. (2021). Visual Aura. In: Henderson, A.D., Carey, A.R. (eds) Controversies in Neuro-Ophthalmic Management. Springer, Cham. https://doi.org/10.1007/978-3-030-74103-7_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-74103-7_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-74102-0

  • Online ISBN: 978-3-030-74103-7

  • eBook Packages: MedicineMedicine (R0)